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ARTICLE
Exceptionally low likelihood of Alzheimer’s
dementia in APOE2 homozygotes from a
5,000-person neuropathological study
Eric M. Reiman et al.#
Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk
of Alzheimer’s dementia, while the APOE2 allele is associated with a lower risk of Alzheimer’s
dementia, it is not yet known whether APOE2 homozygotes have a particularly low risk. We
generated Alzheimer’s dementia odds ratios and other findings in more than 5,000 clinically
characterized and neuropathologically characterized Alzheimer’s dementia cases and con-
trols. APOE2/2 was associated with a low Alzheimer’s dementia odds ratios compared to
APOE2/3 and 3/3, and an exceptionally low odds ratio compared to APOE4/4, and the
impact of APOE2 and APOE4 gene dose was significantly greater in the neuropathologically
confirmed group than in more than 24,000 neuropathologically unconfirmed cases and
controls. Finding and targeting the factors by which APOE and its variants influence Alz-
heimer’s disease could have a major impact on the understanding, treatment and prevention
of the disease.
https://doi.org/10.1038/s41467-019-14279-8 OPEN
#A full list of authors and their affiliations appears at the end of the paper.
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Apolipoprotein E (APOE), the major susceptibility gene forlate-onset Alzheimer’s disease (AD), has three commonalleles (APOE2, 3, and 4), giving rise to six genotypes
(APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4). Compared to the most
common APOE3/3 genotype, each additional copy of the APOE4
allele is associated with a higher risk of Alzheimer’s dementia and
a younger mean age at dementia onset, such that APOE4
homozygotes are at the highest risk, while the presence of one or
two copies of the APOE2 allele is associated with a lower risk
of Alzheimer’s dementia and an older mean age at dementia
onset1–4. It remains to be clarified whether APOE2 homozygotes
have a lower odd than persons with the APOE2/3 genotype—a
question we sought to address in an unusually large number of
clinically and neuropathologically classified Alzheimer’s dementia
cases and controls.
We recently discovered two copies of the rare APOE3
Christchurch (APOE3ch [Arg136→Ser]) mutation, located in
the ApoE protein’s low-density lipoprotein receptor (LDLR)
binding region, in an amyloid-β42 (Aβ42)-overproducing pre-
senilin 1 (PSEN1) E280A mutation carrier from the world’s
largest autosomal dominant AD (ADAD) kindred who did not
develop mild cognitive impairment (MCI) until her 70s, nearly
three decades after her kindred’s mean age at MCI onset5.
Using positron-emission tomography (PET) to compare her to
other PSEN1 E280A mutation carriers with MCI, she had the
greatest fibrillar amyloid-β (Aβ) burden (the major constituent
of neuritic plaques), limited paired helical filament (PHF) tau
(neurofibrillary tangle) burden, and minimal glucose hypome-
tabolism in brain regions preferentially affected by AD. Like
5–10% of APOE2 homozygotes, she also had hyperlipoprotei-
nemia Type III, reflecting reduced binding of the ApoE to
LDLR5,6. Like the ApoE2 protein, the ApoEch protein was
associated with less Aβ42 aggregation than the ApoE3 protein
in vitro5,7. Since an APOE2 homozygote with an ADAD
mutation did not have a significantly delayed clinical onset of
ADAD, we postulated that homozygosity for APOEch may be
more protective than homozygosity for APOE2, but that
APOE2 homozygotes might still have an exceptionally low risk
of late-onset Alzheimer’s dementia. We also postulated that
APOE2 and APOE4 allelic dose would have a more profound
impact on Alzheimer’s dementia odds ratios (ORs) in neuro-
pathologically confirmed than in unconfirmed cases and con-
trols due to the exclusion of clinically diagnosed cases who did
not meet the neuropathological criteria for AD and unimpaired
controls who met the criteria for AD, since misclassified cases
and controls could dilute and/or bias OR estimates in the
unconfirmed group.
This possibility has remained unaddressed, because
case–control studies without neuropathological or biomarker
assessments of AD may have underestimated the impact of APOE
genotypes on Alzheimer’s dementia ORs due to the confounding
effects of APOE genotypes on the percentages of neuropatholo-
gically misclassified cases and controls8–10. In fact, APOE4 non-
carriers tend to be misclassified more frequently, such that 13% of
APOE4 carriers versus 37% of non-carriers with the clinical
diagnosis of mild-to-moderate Alzheimer’s dementia do not meet
neuropathological criteria for AD8. Also, previous studies of
clinically and neuropathologically characterized cases and con-
trols may have been too small to demonstrate that APOE2
homozygotes have an even lower OR than the relatively low-risk
APOE2/3 group due to the paucity of APOE2 homozygotes, who
comprise <1% of the general population1,4.
This study sought to establish that APOE2 homozygotes have
an exceptionally low likelihood of Alzheimer’s dementia,
demonstrate the value of AD risk assessments in clinically and
neuropathologically characterized cases and controls, and
underscore the impact of different APOE genotypes on Alzhei-
mer’s dementia ORs relative to the lowest risk APOE2/2 and
highest risk APOE4/4 genotypes. More generally, it sought to
highlight the impact of discovering and targeting the mechanism
by which APOE variants account for differential risk could have
on the understanding, treatment, and prevention of AD, includ-
ing those interventions that might prevent both the initial
development of AD pathology and the subsequent development
of dementia.
Results
Neuropathologically confirmed and unconfirmed groups.
Supplementary Table 1 shows the number of Alzheimer’s
dementia cases and cognitively unimpaired controls for each
APOE genotype in (a) the Alzheimer’s Disease Genetics Con-
sortium (ADGC’s) clinically characterized and neuropathologi-
cally confirmed autopsy group, (b) its clinically characterized but
neuropathologically unconfirmed clinical group, and (c) the
combined neuropathological and clinical group. The 5007 parti-
cipants in the neuropathologically confirmed cohort included
4018 AD dementia cases and 989 cognitively unimpaired and
neuropathologically unaffected controls. The 23,857 participants
in the clinically classified but neuropathologically unconfirmed
cohort included 10,430 probable AD dementia cases and 13,426
cognitively unimpaired controls. The 28,864 participants in the
combined group included 14,448 cases and 14,416 controls.
Supplementary Table 2 summarizes ages at dementia onset in the
cases, ages at last clinical exam in the cases, and ages at death in
the neuropathologically confirmed autopsy cohort.
Alzheimer’s dementia ORs. Table 1 and Supplementary Table 3
show Alzheimer’s dementia ORs for each APOE genotype and
allelic doses (i.e., the number of APOE2 alleles in APOE4 non-
carriers and the number of APOE4 alleles in APOE2 non-car-
riers) before and after adjustment for age and sex in the neuro-
pathologically confirmed and unconfirmed groups before and
after adjustment for age and sex, compared to the common
APOE3/3 genotype. ORs associated with APOE2 allelic dose in
APOE4 non-carriers (APOE2/2 < 2/3 < 3/3) and APOE4 allelic
dose in APOE2 non-carriers (APOE4/4 > 3/4 > 3/3) were gener-
ated using allelic association tests in an additive genetic model. As
discussed below, APOE2/2, APOE2/3, and APOE2 allelic dose
ORs were significantly lower, and APOE3/4, APOE4/4, and
APOE4 allelic dose ORs were significantly higher, in the neuro-
pathologically confirmed group than in the unconfirmed group.
While ORs for the other APOE genotypes were similar to those
that we had reported in a small number of cases and controls, the
number of APOE2 homozygotes in the earlier study was too small
to provide an accurate OR estimate1,11. Table 2 shows Alzhei-
mer’s dementia ORs for each APOE genotype compared to the
relatively low-risk APOE2/3 and highest risk APOE4 genotypes
in the neuropathologically confirmed cohort. As discussed below,
these ORs permitted us to confirm our primary hypothesis that
APOE2/2 is associated with a significantly lower OR compared to
APOE3/3 and to demonstrate an exceptionally low OR compared
to APOE4/4. Supplementary Table 4 shows Alzheimer’s dementia
ORs for each APOE genotype in the combined group, compared
to APOE3/3, and for APOE2 and APOE4 allelic dose before and
after adjustment for age, sex, and autopsy/non-autopsy group.
As shown in Tables 1 and 2, APOE2 homozygotes in the
neuropathologically confirmed group had a significantly lower
0.34 OR (95% confidence interval (CI)= 0.12–0.95) compared
to the relatively low-risk APOE2/3 genotype, an extremely
low 0.13 OR (95% CI= 0.05–0.36) compared to the most
common APOE3/3 genotype; and an exceptionally low 0.004
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OR (95% CI= 0.001–0.014) compared to the highest risk
APOE4/4 genotype. As shown in Supplementary Tables 3 and
4, APOE2 homozygotes had more modest, but significantly lower
ORs compared to APOE3/3 in both the clinical group (0.52 OR;
95% CI= 0.30–0.90) and the combined group (0.43 OR; 95%
CI= 0.26–0.70), while ORs in the neuropathologically confirmed,
unconfirmed, or combined group were not significantly affected
after adjustment for age and sex.
As shown in Table 1, APOE2 allelic dose in APOE4 non-
carriers was associated with significantly lower ORs in both the
neuropathologically confirmed and unconfirmed groups, and
with significantly lower ORs in the confirmed group than in the
unconfirmed group (Table 1). As shown in Supplementary
Tables 3 and 4, ORs in the neuropathologically confirmed (0.38
OR; 95% CI= 0.30–0.48; P= 1 × 10−15), unconfirmed (0.64 OR;
95% CI= 0.58–0.72; P= 2 × 10−16), and combined groups (0.59
OR; 95% CI= 0.53–0.65; P= 9 × 10−27) were similar to the
corresponding APOE2/3 ORs relative to APOE3/3. These
findings were not significantly affected after adjustment for age,
sex, and neuropathologically confirmed autopsy/unconfirmed
non-autopsy group.
APOE2/4, APOE3/4, and APOE4/4 genotypes compared to the
most common APOE3/3 genotype in the neuropathologically
confirmed autopsy group were associated with 2.68, 6.13, and
31.22 ORs, respectively. These APOE4 carrying genotypes
compared to the lowest risk APOE2/2 genotype increased ORs
with 20.33, 46.51, and 236.74, respectively, while, compared to the
highest odds APOE4/4 genotype decreased ORs with 0.09, 0.20,
and 1.00, respectively. These results underscore the impact of
APOE and its common APOE genotypes on the differential
associations of Alzheimer’s dementia, the progressively harmful
or protective molecular mechanisms that may account for these
differences, and the importance of discovering interventions to
safely and sufficiently target those factors to the treatment and
prevention of AD. As we predicted from the likely inclusion of
neuropathologically misclassified cases and controls in the clinical
group, APOE3/4 and 4/4 ORs were significantly lower than those
in the neuropathologically confirmed autopsy group and roughly
comparable to those from numerous case–control studies in
which neuropathological (or biomarker) measurements were not
required to confirm the presence or absence of AD1. APOE2/4, 3/
4, and 4/4 Alzheimer’s dementia ORs relative to APOE3/3 were
2.47, 3.55, and 10.70, in the neuropathologically unconfirmed
group (Table 1), and 2.47, 3.78, and 12.02 in the combined group
(Supplementary Table 4), respectively.
As shown in Table 1 and Supplementary Tables 3 and 4,
APOE4 allelic dose in APOE2 non-carriers was associated with
significantly greater ORs in the neuropathologically confirmed
autopsy, neuropathologically unconfirmed clinical, and combined
groups. Using an additive genetic model, ORs in the neuropatho-
logically confirmed (6.00 OR; 95% CI= 5.06–7.12; P= 3 × 10−90),
unconfirmed (3.43 OR; 95% CI= 3.26–3.60; P < 1 × 10−300), and
combined group (3.61 OR; 95% CI= 3.37–3.87; P= 2 × 10−290)
were similar to corresponding APOE3/4 OR relative to APOE3/3.
As shown in Supplementary Tables 3 and 4, findings were not
significantly different after adjustment for age or sex in the
neuropathologically confirmed or unconfirmed group or after
adjustment for age, sex, or neuropathologically confirmed
autopsy/unconfirmed non-autopsy group.
The receiver operating characteristic (ROC) curves in Supple-
mentary Fig. 1 show the impact of APOE2 and APOE4 allelic
doses on the classification of cases and controls in the
neuropathologically confirmed autopsy and unconfirmed non-
autopsy groups. APOE2 and APOE4 allelic doses were each
Table 2 Association of each APOE genotype in the neuropathologically confirmed group.
APOE Compared to APOE2/3 Compared to APOE4/4
OR 95% CI P OR 95% CI P
2/2 0.34 0.12–0.95 0.04 0.004 0.001–0.014 6.0 × 10−19
2/3 Ref. Ref. Ref. 0.012 0.006–0.024 1.2 × 10−34
3/3 2.60 2.00–3.38 1.6 × 10−12 0.032 0.017–0.060 4.9 × 10−26
2/4 6.96 4.06–11.92 7.5 × 10−12 0.086 0.039–0.189 1.6 × 10−9
3/4 15.92 11.85–21.38 1.4 × 10−70 0.196 0.103–0.375 8.4 × 10−7
4/4 81.05 41.39–158.68 1.2 × 10−34 Ref. Ref. Ref.
Alzheimer’s dementia odds ratios (ORs), 95% confidence intervals (CIs), and P value (P) for each APOE genotype compared to the APOE2/3 or 4/4 genotype as a reference (Ref.) in the
neuropathologically confirmed group were calculated under a logistic regression model.
Table 1 Association of APOE genotypes and allelic doses compared to the APOE3/3 genotype.
APOE Neuropathologically confirmed group Neuropathologically unconfirmed group
OR 95% CI P OR 95% CI P
Genotype
2/2 0.13 0.05–0.36 6.3 × 10−5 0.52 0.30–0.90 0.02
2/3 0.39 0.30–0.50 1.6 × 10−12 0.63 0.53–0.75 2.2 × 10−7
2/4 2.68 1.65–4.36 7.5 × 10−5 2.47 2.02–3.01 5.7 × 10−19
3/4 6.13 5.08–7.41 2.2 × 10−75 3.55 3.17–3.98 2.3 × 10−105
4/4 31.22 16.59–58.75 4.9 × 10−26 10.70 9.12–12.56 7.5 × 10−186
Allelic dose
2 0.38 0.30–0.48 1.1 × 10−15 0.64 0.58–0.72 2.2 × 10−16
4 6.00 5.06–7.12 3.4 × 10−90 3.43 3.26–3.60 <10−300
For genotypic association tests, odds ratio (OR), 95% confidence interval (CI), and P value (P) for each APOE genotype compared to the APOE3/3 genotype were calculated under a logistic
regression model.
For allelic association tests, OR, CI, and P associated with APOE2 allelic dose in APOE4 non-carriers (APOE2/2 < 2/3 < 3/3) and APOE4 allelic dose in APOE2 non-carriers (APOE4/4 > 3/4 > 3/3) in an
additive genetic model were generated under a logistic regression model.
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associated with significantly greater areas under the curve (AUC),
an indicator of classification accuracy, in the neuropathologically
confirmed and unconfirmed groups, and APOE4 allelic dose had
a greater impact than APOE2 allelic dose on AUCs in both
groups. While APOE2 allelic dose was associated with a
significantly greater AUC in the neuropathologically confirmed
autopsy than in the unconfirmed non-autopsy group (AUC 0.68
[95% CI: 0.65–70] versus 0.58 [95% CI: 0.50–0.65]), correspond-
ing to variance importance scores of 24.0 versus 9.0, respectively,
AUCs for APOE4 allelic dose were not significantly different in
the neuropathologically confirmed autopsy and non-autopsy
groups, as reflected by AUC 0.77 (95% CI: 0.75–79) versus 0.75
(95% CI: 0.74–0.77) and corresponding variance importance
scores of 43.9 and 32.3.
ORs for four other neuropathological diseases. Other neuro-
pathological diseases are relatively common in older adults with
and without Alzheimer’s dementia. Supplementary Table 5 shows
the number of persons in the neuropathologically confirmed
case–control group with and without four commonly assessed
neuropathological diagnoses, including congophilic amyloid
angiopathy (CAA), Lewy body disease (LBD), vascular brain
injury (VBI), and hippocampal sclerosis (HS). (Since TDP-43
pathology and microinfarcts were not characterized in many of
the participants, they were not included in our analysis.) CAA,
LBD, VBI, and HS were present in 94%, 88%, 78%, and 83% of
the Alzheimer’s dementia cases and 70%, 22%, 12%, and 14% of
the unimpaired non-AD controls. Supplementary Tables 6 and 7
show CAA, LBD, VBI, and HS ORs for each APOE genotype,
compared to APOE3/3, and for allelic dose, before and after
adjustment for age, sex, and the neuropathological diagnosis of
AD. APOE2 allelic dose was not associated with a significantly
lower OR for any of these diseases, before or after adjustment for
the presence or absence of AD. While APOE4 allelic dose was not
significantly associated with significantly higher VBI and HS ORs,
it was associated with significantly higher CAA and LBD ORs,
before and after adjustment for age, sex, and presence or
absence of AD.
Ages at dementia onset. The estimated mean ages at Alzheimer’s
dementia onset for each genotype shown in Supplementary
Table 2 are consistent with previously reported findings. In
neuropathologically confirmed Alzheimer’s dementia cases with
available onset ages, APOE4/4, 3/4, 2/4, 3/3, and combined 2/3
and 2/2 genotypes were associated with progressively older ages at
Alzheimer’s dementia onset, ranging from 69.9 ± 6.1 years in the
APOE4/4 genotype to 79.3 ± 9.0 years in the combined APOE2/3
and 2/2 group. In the neuropathologically unconfirmed and
combined cases, APOE4/4, 3/4, 2/4, 3/3, and combined 2/3 and 2/
2 genotypes were also associated with progressively older ages at
Alzheimer’s dementia onset, ranging from 69.5 ± 5.9 years in the
combined APOE4/4 homozygote group to 77.7 ± 8.5 years in the
combined APOE2/3 and 2/2 group. We used age at death as a
proxy age when age at onset in cases were not available. The
Kaplan–Meier curves in Fig. 1 show the percentage of persons in
the neuropathologically confirmed case–control group with each
APOE genotype, including APOE2/2, who remained free from
Alzheimer’s dementia at different ages. While there was some
overlap between the 95% CIs in the APOE2/2 and 2/3 plots due to
the small size of and relatively large CI for the APOE2/2 group,
the Kaplan–Meier plots in Fig. 1 confirmed a relationship
between APOE2 allelic dose and freedom from Alzheimer’s
dementia survival at older ages.
Neuritic plaque and neurofibrillary tangle severity. Supple-
mentary Table 8 and Supplementary Fig. 2 provide information
about Consortium to Establish a Registry (CERAD) (neuritic Aβ
plaque) scores and Braak (tau tangle) stage in the neuropatho-
logically verified case–control group, which contained only
neuropathologically confirmed AD cases and pathology-free
controls. APOE genotype (APOE2/2 < 2/3 < 3/3 < 2/4 < 3/4 < 4/
4) (and consequently allelic dose) were associated with greater
Aβ plaque and tau tangle severity, before and after adjustment
for age at death and sex. Our findings could be attributable to
the proportion of cases to controls in each genetic group, their
direct or indirect impact on these neuropathological features,
potentially confounding differential effects of AD onset and
duration on Braak stage, or a combination of these and other
factors. While the difference between CERAD scores in the
small APOE2/2 and 2/3 groups were not significant (1.05 ± 1.10
versus 1.33 ± 1.31, P= 0.35), APOE2 homozygotes were dis-
tinguished from the APOE2/3 group by a significantly lower
Braak stage (2.26 ± 1.63 versus 3.16 ± 1.69, P < 0.05), before and
after adjustment for age and sex. Compared to the APOE3/3
group, the APOE2/2 and APOE2/3 groups had significantly
lower CERAD scores and Braak stages, and the APOE2/4, 3/4,
and 4/4 genotypes had significantly higher CERAD scores and
Braak stages, before and after adjustment for age at death
and sex.
Residual effects of each APOE genotype on Braak stage, relative
to APOE2/2, 3/3, and 4/4, after controlling CERAD scores are
depicted in terms of β (linear regression) coefficients in Table 3.
Relatively protective or harmful effects are reflected by negative or
positive β coefficients, respectively. Compared to APOE2/3 or
APOE3/3, only the APOE3/4 and 4/4 genotypes demonstrated
progressively harmful residual effects on Braak stage. Compared
to APOE4/4, the APOE2/2, 2/3, 3/3, 2/4, and 3/4 genotypes had
significant and progressively protective residual effects on Braak
stage with β coefficients of −1.32, −0.43, −0.25, −0.26, and
−0.10, respectively (P < 0.05), such that the protective effect was
more than three times greater in the APOE2/2 group than in the
APOE2/3 group. This finding supports the possibility that APOE
variants have differential effects on tau tangle severity, even after
controlling for neuritic Aβ plaque severity.
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Fig. 1 Percent free from Alzheimer’s dementia. Kaplan–Meier curves were
generated from Alzheimer’s dementia cases and cognitively unimpaired
non-AD controls in the neuropathologically confirmed group. Y-axis
represents the percentage of persons with each APOE genotype in the
neuropathologically confirmed group who remained free from Alzheimer’s
dementia. X-axis denotes age at death for controls and age at onset of
cases, while replacing with age at death when age at onset was unavailable.
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Discussion
This study demonstrates an exceptionally low likelihood of Alz-
heimer’s dementia in APOE2 homozygotes in a large group of
clinically and neuropathologically characterized cases and con-
trols. The large number of cases and controls in the neuro-
pathologically unconfirmed and combined groups enabled us to
demonstrate a significantly greater impact of APOE2/2, 2/3, 3/3,
3/4, and 4/4 genotypes on Alzheimer’s dementia ORs in the
neuropathologically confirmed group—and to suggest that the
greater impact may be attributable to the exclusion of cases
without significant AD neuropathology, as well as the exclusion
of controls with preclinical AD neuropathology12. This study
provides updated ORs for Alzheimer’s dementia for each of the
six common APOE genotypes, APOE2 allelic dose, and APOE4
allelic dose on, on the differential risk of Alzheimer’s dementia,
free from the confounding effects of clinically misdiagnosed cases
and controls, and it demonstrates an additional impact of
APOE4, but not APOE2 allelic dose on two other neuropatho-
logical disease (CAA and DLB) ORs. The study supports known
effects of APOE genotypes on standard measures of neuritic Aβ
plaque and tau tangle severity13 and suggests progressively pro-
tective residual effects on Braak stage in APOE3/4, 2/4, 3/3, 2/3,
and 2/2 groups compared to APOE4/4 homozygotes.
The APOE2/2 genotype was associated with a significantly
lower 0.34 Alzheimer’s dementia OR compared to the relatively
low odds APOE2/3 genotype (95% CI: 0.12–0.95), an extremely
low 0.13 OR compared to the most common APOE3/3 genotype
(95% CI: 0.05–0.36), and an exceptionally low 0.004 OR com-
pared to the highest odds APOE4/4 genotype (95% CI:
0.001–0.014) in those neuropathologically confirmed subjects. In
other words, persons with the APOE2/2 genotype had a 66%
lower OR than those with the APOE2/3 genotype, 87% lower
than those with the APOE3/3 genotype, and 99.6% (95% CI:
98.6–99.9%) lower than those with APOE4/4 group. These find-
ings highlight the impact of APOE and its variants on the risk of
AD and the potential impact of APOE-modifying interventions
on its treatment and prevention.
The APOE2/2 genotype has recently been suggested to be
associated with more severe pathology in primary tauopathies,
including progressive supranuclear palsy, corticobasal degenera-
tion, and a mouse model of human tau over-expression14. On the
other hand, APOE2/2 and APOE3/3ch genotypes could be
associated with less severe tau pathology in AD (a secondary
tauopathy) due to a direct or indirect (e.g., amyloid and neu-
roinflammation-mediated) effects, as noted above. While the
current study did not assess the impact of APOE2 allelic dose on
ORs for these primary tauopathies, it found no association
between APOE2 allele dose and ORs for four other disease (CAA,
DLB, VBI, and HS). In contrast, APOE4 allelic dose was asso-
ciated with significantly higher ORs for CAA and DLB, before
and after adjustment for the presence or absence of AD, and not
with VBI or HS11. These findings are similar to those described in
a study involving many of these cases and controls, even though
we did not include persons with the APOE3/4 genotype in our
assessment of APOE2 and APOE4 allelic doses.
As previously noted, we and our colleagues recently found as
association between two copies of the rare APOE3ch mutation
and resistance to the clinical onset of AD in an Aβ42-over-
producing PSEN1 E280A mutation carrier from the world’s lar-
gest ADAD kindred5. Interestingly, this individual had unusually
high PET measurements of Aβ plaque burden, relatively limited
PET measurements of PHF tau (neurofibrillary tangle) burden,
minimal cerebral glucose hypometabolism in AD-affected brain
regions, and like some APOE2 homozygotes, Type III hyperli-
poproteinemia5,6. Associations between APOE variants and AD
(APOE4 > 3 > 2 and APOE3ch) and other findings led us to
postulate that the contributions of APOE and its variants to the
differential risk of Alzheimer’s dementia are not solely attribu-
table to their impact on the density of Aβ plaques but also to their
direct or indirect impact on downstream pathogenic events. In
experimental studies, we found that the ApoEch protein was
associated with reduced Aβ42 burden and a differential impact of
ApoE isoforms (ApoE4 > 3 > 2 >> 3ch) on heparin binding, and
demonstrated the ability of a targeted antibody to lower wild-type
ApoE3 binding15. Based on studies implicating heparin sulfate
polyglycan (HSPG) on Aβ aggregation, Aβ-mediated microglial
response, and the neuronal uptake and propagation of tau, and
neurodegeneration, we postulated that the ApoE binding to
HSPG could have potential roles in the pathogenesis, treatment,
and prevention of AD16.
Together, our APOE2/2 and APOE3ch/3ch studies underscore
the need to clarify and target the factors by which APOE and its
variants account for this differential risk, treatment, and pre-
vention of AD. It remains to be shown whether the differential
effects of APOE variants on the risk of Alzheimer’s dementia are
related to their recognized effects on Aβ oligomerization5–7,
morphology, or clearance, their suggested effects on TREM2-
mediated microglial response, tau pathology, LDLR binding,
HSPG binding, mitochondrial function, neurodegeneration, a
non-additive protective effect of APOE2 in reducing the expres-
sion of a microglial aging signature (HuMi Aged geneset)17, or a
combination of these and other effects5,7,18–23. It also remains to
be shown whether it would help to increase or, as some of us
suggest, decrease ApoE expression in the brain, and whether
ApoEch and ApoE2 isoforms might be associated with a relative
loss in one or more functions that are critically involved in the
development of AD. If so, APOE and its variants could differ in
the extent of their pathogenic functions (APOE4/4 > 3/4 > 2/4 >
3/3 > 2/3 > 2/2 > APOEch/ch > no APOE)5. We postulate that
genetic, drug, or immune treatments that safely and sufficiently
inhibit the expression of APOE or its relevant functions in brain
might have a significant impact on the treatment and prevention
Table 3 Residual effects of Braak stage after adjustment for plaque core.
APOE Compared to APOE2/3 Compared to APOE3/3 Compared to APOE4/4
BETA SE P BETA SE P BETA SE P
2/2 −0.44 0.31 0.15 −0.50 0.28 0.07 −1.32 0.27 1.6 × 10−6
2/3 Ref. Ref. Ref. −0.07 0.09 0.44 −0.43 0.11 1.2 × 10−4
3/3 0.07 0.09 0.39 Ref. Ref. Ref. −0.25 0.06 4.3 × 10−5
2/4 0.13 0.16 0.40 0.03 0.12 0.80 −0.26 0.11 0.02
3/4 0.29 0.08 6.1 × 10−4 0.15 0.04 1.9 × 10−4 −0.10 0.05 0.05
4/4 0.42 0.10 7.5 × 10−5 0.25 0.06 4.3 × 10−5 Ref. Ref. Ref.
β estimate (BETA), standard error (SE), and P (P value) for each APOE genotype compared to the APOE2/3, 3/3, and 4/4 genotype as a reference (Ref.) were calculated under a linear regression model;
NA: not applicable. β estimates reflect the impact of each APOE genotype on Braak (tau tangle) stage after adjustment for CERAD (neuritic Aβ plaque) score.
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of AD. Evidence from a person without APOE function due to
homozygosity for an ablative APOE frameshift mutation24 and
the availability of dyslipidemia treatments support the potential
tolerability of this approach. Additional research is needed to
clarify the mechanisms by which homozygosity for APOE2 and
APOEch are associated with an exceptionally low risk of AD
dementia. Gene editing, protein-reducing, protein-modifying, or
other treatments that safely and sufficiently replicate protective
effects of the APOE2/2 genotypes could help to prevent the
clinical onset of AD.
The study has several limitations. First, while the unusually
large number of participants in the overall study, there was a
relatively small number of APOE2 homozygotes. Despite the
resulting limitation in statistical power, it did not prevent us from
demonstrating significant effects in association with the APOE2/2
genotype and APOE2 allelic dose. Second, as previously noted,
since we do not have information from most of the participating
brain banks’ neuropathologically misclassified cases and controls,
we are not able to clarify with the more profound impact of
different APOE genotypes and allelic doses on Alzheimer’s
dementia ORs is solely attributable to the exclusion of neuro-
pathologically misclassified cases and controls or also to any
ascertain biases related to participation in a brain donation pro-
gram. However, we were able to quantify and distinguish the
impact of APOE2 versus APOE4 allelic doses on the classification
of cases and controls in both the neuropathologically confirmed
and unconfirmed groups. Third, we cannot exclude an impact of
differential disease onset, duration, or survival on Alzheimer’s
dementia ORs and measures of AD pathology. Fourth, findings
from our non-Hispanic White groups cannot yet be extended to
other ethnic and racial groups4.
Prospective cohort studies that include persons irrespective of
their cognitive stage or neuropathological diagnosis are needed to
clarify the absolute lifetime risk of neuropathologically confirmed
Alzheimer’s dementia for each APOE genotype. Similarly, neu-
ropathological studies that include brain donors irrespective of
their cognitive stage or neuropathological diagnosis are needed to
further clarify the impact of APOE2 gene dose on tau pathology
and neurodegeneration, including the extent to which this impact
is or is not mediated through its effect on Aβ pathology8,25. Since
the reported prevalence and impact of different APOE genotypes
on Alzheimer’s dementia risk depends in part on age, race, eth-
nicity, geographic location, education, and dementia severity,
these estimates are likely to vary in different populations. Based
on our selection criteria, this study does not provide information
about the percentage of APOE genotypes in cognitively unim-
paired persons with neuropathological or biomarker evidence of
preclinical AD, the percentage of persons who met criteria for
MCI with or without neuropathological or biomarker evidence of
AD, or the percentage of persons with a primary diagnosis of
other neurodegenerative disorders. The impact of different APOE
genotypes on estimated ages at Alzheimer’s dementia onset may
have been greater if standardized prospective assessments had
been used to estimate onset ages at every site, if the study
included more research participants who developed Alzheimer’s
dementia at younger ages (e.g., preferentially reducing onset ages
in the APOE4 carrier groups), and if it included more participants
who developed Alzheimer’s dementia at the oldest ages, for
example, preferentially increasing onset ages in the APOE4 non-
carrier groups.
This study supports the complementary value of risk factor
assessments in large neuropathologically confirmed autopsy and
even larger neuropathologically unconfirmed clinical groups. In a
previous autopsy study, we found that 25% of persons with the
clinical diagnosis of mild-to-moderate Alzheimer’s dementia
lacked at least moderately frequent neuritic plaques, one of the
cardinal features of AD, including 37% of APOE4 non-carriers
and 13% of carriers, findings that are consistent with those in
living patients9,10. In a meta-analysis of brain imaging studies,
about 25% of cognitively unimpaired older adults have brain
imaging evidence consistent with at least moderately frequent
plaques. By investigating clinically characterized cases who are
confirmed to have AD to unimpaired controls who are confirmed
to be free of AD, it may be possible to address potentially con-
founding effects of the risk factor on the presence or absence of
AD and underscore the potential impact of an intervention to
prevent both AD and its clinical consequences. By investigating
an even larger number of cases and controls without biological
confirmation, it may be possible to clarify risk factors without
potentially confounding effects on the underlying disease with
improved statistical power and greater generalizability to under-
studied populations. Brain imaging and fluid biomarkers have the
potential increase the size and generalizability of findings in
case–control studies of AD.
Additional research is needed to clarify the mechanism by
which APOE and its variants contribute to the pathogenesis and
potential treatment and prevention of AD. There is a critical need
to discover treatments that account for impact of genotypes on
the differential risk of Alzheimer’s dementia, including those that
may account for a profound resistance to Alzheimer’s dementia
in APOE2 and APOEch homozygotes, and to establish their value
in the treatment and prevention of AD.
In conclusion, homozygosity for the APOE2 allele appears to
be associated with an exceptionally low likelihood of AD
dementia, APOE genotypes have an important impact on Alz-
heimer’s dementia ORs, and treatments that target APOE and its
variants could have an important impact on the treatment and
prevention of the disease.
Methods
Subjects. Our primary analysis capitalized on data from 5007 brain donors in the
ADGC’s neuropathologically confirmed autopsy group (confirmed group),
including 4018 cases who met the clinical and neuropathological criteria for Alz-
heimer’s dementia and 989 cognitively unimpaired controls who did not meet the
neuropathological criteria for AD were described in prior reports; 5 of the cases
and 19 of the controls had the APOE2/2 genotype. There were 283 brain donors in
the ADGC’s “neuropathologically misclassified autopsy group,” including 123 cases
who met the clinical criteria for probable Alzheimer’s dementia, but did not meet
the neuropathological criteria for AD, and 160 unimpaired controls who met the
neuropathological criteria for AD. The entire autopsy group consisted of unrelated
cases and controls. The ADGC’s neuropathologically unconfirmed clinical group
(unconfirmed group) contained 23,857 living research participants, including
10,430 cases who met the clinical criteria for probable Alzheimer’s dementia and
13,427 cognitively unimpaired controls, and the combined (neuropathologically
confirmed and unconfirmed) group contained 28,864 research participants,
including 14,448 cases and 14,416 controls. Data from the neuropathologically
confirmed autopsy group were used in our primary analyses; data from the other
groups were in post hoc comparisons with that in the autopsy group. Due to the
prioritized ascertainment of those cases who met the clinical and neuropathological
criteria for Alzheimer’s dementia and those unimpaired controls without AD, the
number of misclassified cases and controls available through the AD Genetics
Consortium12 is much smaller than our estimated number of neuropathologically
misclassified cases and controls8–11, limiting our ability to clarify the impact of
brain donation on APOE ORs in our post hoc analyses. The number of cases and
controls for each APOE genotype in the ADGC’s neuropathologically confirmed
autopsy group, neuropathologically unconfirmed clinical group, and combined
confirmed and unconfirmed group is shown in Supplementary Table 1.
Phenotypic evaluation. Brain samples, extracted DNA, and demographic, clinical,
and neuropathological data from clinically and neuropathologically characterized
brain donors were assembled by the ADGC in conjunction with past and present
National Institute on Aging (NIA)-sponsored AD Centers, Banner Sun Health
Research Institute and the Translational Genomics Research Institute (TGen), the
Adult Changes in Thought Study (ACT), the University of Miami’s Brain
Endowment Bank and Hussman Institute for Human Genomics, the Late-onset
Alzheimer’s Disease Family Study, the Religious Orders Study and Memory Aging
Project (ROS-MAP), the Vanderbilt University Center for Human Genetics
Research, and the National Alzheimer’s Coordinating Center; APOE genotypes
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were characterized at the National Cellular Repository for AD or TGen. Neuritic
plaque burden was scored using the CERAD 0–3 point (none, sparse, moderate, or
frequent plaque) rating system, the spatial extent of neurofibrillary tangle (PHF
tau) burden was scored using the Braak 0–VI staging system, and neuropatholo-
gical data were reviewed and harmonized by a single neuropathologist (Thomas
Montine)11,13. Neuropathological data in the autopsy group was collected at each
site according to consensus guidelines at the time of brain autopsy. Cases with
neuropathologic evidence of disease other than AD neuropathologic change, with
or without common co-morbid lesions, were excluded. CERAD score, which
provide an indicator of neuritic (Aβ) plaque severity, and Braak stage, which
provides an indicator of neurofibrillary (tau) tangle spatial extent and severity, were
available in every participant in the ADGC’s neuropathologically confirmed
case–control autopsy group. Data regarding the presence or absence of four other
neuropathological diagnoses commonly found in persons with AD, including CAA,
LBD, VBI, and HS, was most of the participants. Since TDP-43 proteinopathy and
microinfarcts were not available in most of the brain donors (many of whom came
to autopsy prior to development of TDP-43 proteinopathy), these neuropatholo-
gical diseases were not included in our analysis. CAA, LBD, VBI, and HS were
present in 84%, 43%, 38%, and 21% of the Alzheimer’s dementia cases and
unimpaired non-AD controls.
The Alzheimer’s dementia cases met the DSM-IV or NINCDS/ADRDA criteria
for dementia26 and, when available, had Clinical Diagnostic Ratings (CDRs) greater
than zero before they died27; they either met the NIA/Reagan neuropathological
criteria for intermediate-to-high likelihood AD or had both moderate-to-frequent
neuritic plaque scores (i.e., CERAD score 2–3) and spatially extensive
neurofibrillary tangle burden (i.e., Braak stage III–VI)28–30. The controls did not
meet the clinical criteria for dementia or MCI and, when available, had a CDR of
zero, within 2 years before they died; they met the neuropathological criteria for
low-likelihood AD, had sparse neuritic plaques (CERAD score 1) and spatially
limited tangle burden (Braak stages 0–II), or had no neuritic plaques (CERAD
score 0) and no more than moderately extensive tangle burden (Braak stages 0–IV).
For comparative purposes, we subsequently analyzed APOE and other relevant
data in clinically diagnosed but neuropathologically unexamined participants
assembled by the ADGC from non-Hispanic whites. Ages at clinical onset (when
available), last clinical examination, and age at death of the ADGC sample31 are
shown for each APOE genotype in Supplementary Tables 2 and 3.
Statistical analysis. For the assessment of Alzheimer’s dementia ORs associated
with each APOE genotype, we coded the APOE genotype of interest as 1, coded the
reference genotype as 0 (APOE2/2, APOE3/3, or APOE4/4), and treated other
genotypes as missing. We used clinical diagnosis as a binary outcome (AD) for the
neuropathologically confirmed, clinical, and combined group. ORs and 95% CIs for
each APOE genotype were computed compared to a reference APOE genotype. We
conducted genotypic association tests for each APOE genotype compared to a
reference genotype used for AD, CAA, LBD, VBI, and HS with and without
covariate adjustment for age and sex. For the neuropathologically confirmed group,
we computed ORs under a logistic regression using a generalized linear model
(GLM). For clinical and combined groups, we further accounted for family
structure due to containing families from the Multi-Institutional Research on
Alzheimer’s Genetic Epidemiology and NIA Late-onset AD (NIA-LOAD) study32
under a logistic regression using generalized estimating equations. For the
assessment of APOE2 allelic dose treating APOE2 or APOE4 allele as a bi-allelic
genetic variant, we coded APOE3/3, APOE2/3, and APOE2/2 as 0, 1, 2, respec-
tively, in the APOE4 non-carriers; and for the assessment of APOE4 allelic dose, we
coded APOE3/3, APOE3/4, and APOE4/4 as 0, 1, 2, respectively, in the APOE2
non-carriers. We conducted allelic association tests for the APOE2 and APOE4
under a logistic regression using a GLM for AD, CAA, LBD, VBI, and HS with and
without covariate adjustment for age and sex. We further adjusted for AD in four
other neuropathological diagnoses, CAA, LBD, VBI, and HS We used a sensitivity
analysis, ROC curves, and AUCs to characterize and compare the contribution of
APOE2 and APOE4 allelic doses on the classification of cases and controls in the
neuropathologically confirmed and unconfirmed groups. To rank predictors based
on their contributions to the logistic regression model, we calculated variance
importance score using the varImp option in R, which the importance score is
ranged from 0 to 100%.
Data from the neuropathologically confirmed group were used to generate the
Kaplan–Meier curves for each APOE genotype that are shown in Fig. 1. The curves
indicate the percentage of neuropathologically confirmed cases and controls who
remained free from Alzheimer’s dementia as a function of age. When estimated
ages at dementia onset were not available, ages at death were used as a proxy.
CERAD scores and Braak stages were quantified for each APOE genotype in the
aggregate group of neuropathologically confirmed cases and controls. Linear
regression using the GLM model was used to assess the effect of each APOE
genotype comparing to the reference genotype for CERAD and Braak
measurements as quantitative outcomes with or without age at death and sex as
covariates, repeated using CERAD scores as a covariate to assess residual effects of
Braak stage.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
APOE genotype and clinical/neuropathological phenotype data from ACT, ANDI, and
ROS-MAP studies are accessible by directly applying to their study websites. APOE
genotype and clinical/neuropathological phenotype data from other studies can be
accessed by applying directly to The National Institute on Aging Genetics of Alzheimer’s
Disease Data Storage Site (NIAGADS)—an NIA/NIH-sanctioned qualified-access data
repository, under accession NG00075. The data that support the findings of this study are
available from the NIAGAD website (https://www.niagads.org/).
Code availability
The custom codes in R that generated the findings of this study are available by authors
upon request.
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